Mogensen C E, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts R W, Cooper M E
Department of Medicine, M, Kommunehospitalet, University Hospital, DK-8000 Aarhus C, Denmark.
BMJ. 2000 Dec 9;321(7274):1440-4. doi: 10.1136/bmj.321.7274.1440.
To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes.
Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment.
Tertiary hospitals and primary care centres in four countries (37 centres).
199 patients aged 30-75 years.
Candesartan 16 mg once daily, lisinopril 20 mg once daily.
Blood pressure and urinary albumin:creatinine ratio.
At 12 weeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P<0.001) and 9.7 mm Hg (7.9 mm Hg to 11.5 mm Hg, P<0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P<0.001) and 46% (35% to 56%, P<0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P<0. 001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P<0.001) or lisinopril (mean 10.7 mm Hg, 8.0 mm Hg to 13.5 mm Hg, P<0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater than with candesartan (24%, 0% to 43%, P=0.05) and lisinopril (39%, 20% to 54%, P<0.001). All treatments were generally well tolerated.
Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
评估并比较坎地沙坦或赖诺普利单药治疗以及二者联合治疗对微量白蛋白尿、高血压合并2型糖尿病患者血压及尿白蛋白排泄的影响。
前瞻性、随机、平行组、双盲研究,为期4周的安慰剂导入期,随后12周坎地沙坦或赖诺普利单药治疗,接着是12周单药治疗或联合治疗。
四个国家的三级医院和基层医疗中心(37个中心)。
199名年龄在30 - 75岁的患者。
坎地沙坦每日1次,每次16毫克;赖诺普利每日1次,每次20毫克。
血压和尿白蛋白与肌酐比值。
12周时,坎地沙坦组和赖诺普利组舒张压平均降低值(95%置信区间)分别为9.5毫米汞柱(7.7毫米汞柱至11.2毫米汞柱,P<0.001)和9.7毫米汞柱(7.9毫米汞柱至11.5毫米汞柱,P<0.001),尿白蛋白与肌酐比值分别降低30%(15%至42%,P<0.001)和46%(35%至56%,P<0.001)。24周时,联合治疗组舒张压平均降低值(16.3毫米汞柱,13.6毫米汞柱至18.9毫米汞柱,P<0.001)显著大于坎地沙坦组(10.4毫米汞柱,7.7毫米汞柱至13.1毫米汞柱,P<0.001)或赖诺普利组(平均10.7毫米汞柱,8.0毫米汞柱至13.5毫米汞柱,P<0.001)。此外,联合治疗组尿白蛋白与肌酐比值降低幅度(50%,36%至61%,P<0.001)大于坎地沙坦组(24%,0%至43%,P = 0.05)和赖诺普利组(39%,20%至54%,P<0.001)。所有治疗耐受性普遍良好。
对于高血压合并2型糖尿病患者,每日1次16毫克坎地沙坦在降低血压和微量白蛋白尿方面与每日1次20毫克赖诺普利效果相当。联合治疗耐受性良好且在降低血压方面更有效。